Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FADE-DRT: Antithrombotic Strategies After LAAO
NCT04502017Phase 4Unknown
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) and Device-related thrombosis (DRT) (3 arms), sponsored by Texas Cardiac Arrhythmia Research Foundation. Primary endpoints: Composite of Stroke, Systemic Embolism, and Device-related Thrombosis at 1 year and Incidence of Major Bleeding Events at 1 year. Status: unknown.
02
Conditions
Atrial fibrillation (AFib)Device-related thrombosis (DRT)
Beyond the preview
Go deeper on NCT04502017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502017.